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Abstract
Background: Carboxymethyl lysine is an advanced glycation end product of interest as a potential biomarker of
cardiovascular and other diseases. Available methods involve ELISA, with potential interference, or isotope dilution
mass spectrometry (IDMS), with low-throughput sample preparation.
Methods: A high-throughput sample preparation method based on 96-well plates was developed. Protein-bound
carboxymethyl lysine and lysine were quantified by IDMS using reversed phase chromatography coupled to a high-
resolution accurate mass Orbitrap Exactive mass spectrometer. The carboxymethyl lysine concentration (normalized to
lysine concentration) was measured in 1714 plasma samples from the British Regional Heart Study (BRHS).
Results: For carboxymethyl lysine, the lower limit of quantification (LLOQ) was estimated at 0.16 lM and the assay was
linear between 0.25 and 10lM. For lysine, the LLOQ was estimated at 3.79mM, and the assay was linear between 2.5
and 100mM. The intra-assay coefficient of variation was 17.2% for carboxymethyl lysine, 9.3% for lysine and 10.5% for
normalized carboxymethyl lysine. The inter-assay coefficient of variation was 18.1% for carboxymethyl lysine, 14.8 for
lysine and 16.2% for normalized carboxymethyl lysine. The median and inter-quartile range of all study samples in each
batch were monitored. A mean carboxymethyl lysine concentration of 2.7lM (IQR 2.0–3.2 lM, range 0.2–17.4 lM) and
a mean normalized carboxymethyl lysine concentration of 69lM/M lysine (IQR 54–76 lM/M, range 19–453 lM/M) were
measured in the BRHS.
Conclusion: This high-throughput sample preparation method makes it possible to analyse large cohorts required to
determine the potential of carboxymethyl lysine as a biomarker.
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Introduction
Carboxymethyl lysine (CML) is an advanced glycation
end product (AGE), produced in vivo, particularly
under hyperglycaemic conditions, and available from
the diet.1,2 Increased CML concentrations are
1Institute of Cardiovascular and Medical Sciences (ICAMS), BHF Glasgow
Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
2Glasgow Polyomics, University of Glasgow, Glasgow, UK
3Institute of Quantitive Biology, Biochemistry and Biotechnology,
University of Edinburgh, Edinburgh, UK
4Primary Care and Population Health, Royal Free Campus, University
College London Medical School, London, UK
Corresponding author:
Naomi J Rankin, B2.16 Joseph Black Building, University of Glasgow,
Glasgow G12 8QQ, UK.
Email: naomi.rankin@glasgow.ac.uk
Annals of Clinical Biochemistry
0(0) 1–11
! The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/0004563219830432
journals.sagepub.com/home/acb
associated with cardiovascular disease, diabetic
nephropathy and retinopathy, chronic kidney disease
and others.2–4 CML has been proposed as a potential
biomarker of cardiovascular disease; however, conflict-
ing results have been found.4–6 Enzyme linked immu-
nosorbent assays (ELISAs) are available but suffer
from steric hindrance of the antigen and interference
from endogenous anti-AGE antibodies.1,2 Isotope dilu-
tion mass spectrometry (IDMS) methods are available
for quantification of protein-bound CML, and samples
require chemical reduction, protein denaturation,
hydrolysis and drying prior to IDMS analysis.
Published sample preparation methods are individual
tube-based, which have limited throughput.1,5
Therefore, we developed a high-throughput sample
preparation method using 96-well plates.
Published IDMS methods for CML quantification
rely on multiple reaction monitoring (MRM) detection
using triple quadrupole mass spectrometers (MS).7 In
MRM, the first quadrupole is optimized to select for
the parent ion of interest (CML) based on the mass to
charge ratio (m/z). A collision cell fragments the parent
ions into product ions,7,8 while the third quadrupole is
optimized to select for specific product ions: the quan-
tifier (for quantification) and the qualifier (for verifica-
tion the identity).7–9 As triple quadrupole detectors
provide excellent sensitivity and specificity, even in
complex biofluids, they are widely used in clinical
chemistry laboratories (e.g. toxicology, endocrinology
and new born screening).7–9
There is increasing interest in the use of high-
resolution accurate mass (HRAM) MS for absolute
quantification of ions, including for routine clinical
analysis and clinical research.10,11 HRAM MS relies
on superior mass accuracy (typically sub 3 ppm),
which allows excellent ion selectivity, provided appro-
priate mass-extraction windows (based on the theoret-
ical m/z of the ion of interest) are chosen.10–13 HRAM
MS analysis is commonly run in full scan mode,
enabling the detection of all ionized compounds, with-
out the need to optimize quadrupoles and collision
energies for individual ions.12 The quantitative perfor-
mance of HRAM MS now equals that of triple quad-
rupole mass spectrometry: in terms of sensitivity, mass
accuracy, selectivity, although this does depend on the
conditions, parameters and the metabolite of interest
used.10–12,14 Some of the major advantages of HRAM
MS are that data can be reanalysed retrospectively to
investigate further biomarkers and that those bio-
markers can be more easily identified (based on molec-
ular formula).10–12,14 HRAM MS has been successfully
used to quantify a number of small molecule groups:
over 50 metabolites (including amino acids);14 amino
acids (within 3min);15 drugs and drug metabolites;16
circulating steroids11 and plasma metanephrines.11
We therefore optimized an HRAM IDMS method
to quantify protein-bound CML and lysine and their
deuterated internal standards using an Orbitrap
Exactive mass spectrometer. To account for variation
in plasma total protein concentration and variation
introduced during sample preparation, the CML con-
centration was normalized to the lysine concentra-
tion.5,6 The three measures reported are CML (lM),
lysine (lM) and normalized CML (lM per M lysine).
Methods
Sample preparation
Serum collected from one healthy volunteer, stored at
–80C in multiple aliquots, was used as a quality con-
trol (QC) sample. The Glasgow University Ethics
Committee provided ethical approval for collection of
anonymized samples for QC (Project number
200140133). Unthawed fasting EDTA plasma samples
(n¼ 1714) from the 30th year re-examination of the
British Regional Heart Study (BRHS),17,18 stored at
–80C, were randomized to 21 batches. Approval for
collection was obtained from the local research ethics
committees of the 24 towns where participants were
recruited. All participants provided written informed
consent to participate in the study.18 The study is con-
sistent with the World Medical Association
Declaration of Helsinki. The BRHS is a prospective
study which recruited 7735 men between 1978 and
1980 from 24 British towns. At the 30-year re-
examination, samples were collected from 1722 men
between 2010 and 2012, with the men then being
aged 71 to 92 years.17
A high-throughput 96-well deep-well plate method
of sample preparation based on previously published
methods was developed.1,4–6 Sodium tetraborate
(Sigma, Dorset, UK), sodium borohydride (Alfa
Aesar, Lancashire, UK), trichloroacetic acid (Sigma,
Dorset, UK), hydrochloric acid (Sigma, Dorset, UK)
were used for sample preparation. Plasma samples were
defrosted for 90min and centrifuged at 20,000 g for
5min. Ten microlitres of plasma were added to 300 lL
sodium tetraborate (0.2M)/borohydride (0.1M) buffer
in a 96-well deep-well polypropylene plate (Thermo
Fisher Scientific, Hemel Hempstead, UK). The samples
were chemically reduced overnight at 4C to prevent
further production of CML (or other advanced glyca-
tion end products) during subsequent hydrolysis.1 The
protein was denatured in 20% trichloroacetic acid, and
the pellet was washed in 20% trichloroacetic acid. The
protein pellet was then hydrolysed at 110C in 600 lL
6M hydrochloric acid for 24 h, using a ceramic bead-
bath. After hydrolysis, the samples were dried to com-
pletion at 95C (approximately 24 h). Immediately
2 Annals of Clinical Biochemistry 0(0)
prior to analysis, the samples were spiked with 10 lL of
20 lM CML-d4 (Toronto Research Chemicals,
Ontario, Canada, 98% pure) and 10 lL of 150mM uni-
versally 13C labelled L-lysine:2HCl) (Cambridge
Isotope Laboratories Inc., MA, USA, 98% pure) as
internal standards (ISs) and reconstituted in 270 lL
of 5mM nonafluoropentanoic acid (NFPA) (Sigma,
Dorset, UK) as an ion-pairing agent.
CML (Toronto Research Chemicals, Ontario,
Canada, 96% pure) and lysine (Sigma, Dorset, UK)
were used to prepare calibrator samples: made up in
water and then mixed with IS and NFPA. A seven-
point calibration curve (CML: 0, 0.25, 0.5, 1, 2, 5, 10
lM and lysine: 0, 2.5, 5, 10, 20, 50, 100mM) was used
to quantify both CML and lysine relative to their ISs.
The concentration ranges were chosen based on the
concentrations previously reported using IDMS quan-
tification.1,6 Previous studies demonstrated that acid
hydrolysis of calibration solutions did not alter peak
area; therefore, calibrator samples were not
hydrolysed.1
Chromatography and HRAM mass spectrometry
Chromatography was carried out on an UltiMate 3000
RSLC system (Thermo Fisher Scientific, Hemel
Hempstead, UK) using an ACQUITY UPLC BEH
C18 column (100 mm 2.1 mm, 1.7 lm column,
Waters, Wilmslow) with VanGuard pre-column
(Waters, Wilmslow, UK). Mobile phase A was 5mM
NFPA (Sigma, Dorset, UK) in HPLC grade water
(Fisher, Loughborough, UK). Mobile phase B was
HPLC grade acetonitrile (Fisher, Loughborough,
UK). The column was maintained at 50C, and sam-
ples were eluted with a linear gradient over 9.0min at a
flow rate of 0.3 ml/min. Starting conditions were 90%
mobile phase A, decreasing to 20% between 0.1 to
4.6min; this was held between 4.6 and 6.1min, then
increased to 90% at 6.2min and held until 9.0min to
re-equilibrate the column. The injection volume was
5 lL, and samples were maintained at 5C prior to
injection. For HRAM MS, an Orbitrap Exactive
(Thermo Fisher Scientific, Hemel Hempstead, UK)
was operated in high-resolution full scan positive
mode, at a scan range of 120–250 m/z, a probe temper-
ature of 150C and capillary temperature 275C. The
mass resolution was 50,000, providing a mass accuracy
of less than 1 ppm. A mass calibration was performed
prior to each batch using Pierce LTQ Velos positive ion
calibration solution (Thermo Fisher Scientific, Hemel
Hempstead, UK). TraceFinder 3.3 (Thermo Fisher
Scientific, Hemel Hempstead, UK) was used to auto-
matically detect peaks within expected retention time
and mass extraction windows.
Protein-bound CML and lysine concentrations were
calculated based on integrated areas relative to those of
the ISs. The normalized CML concentration (lM/M
lysine) was calculated from the measured CML and
lysine concentrations observed (CML/lysine
1,000,000). This allows for variation in total protein
concentration to be accounted for, analogous to
reporting HbA1c in relation to haemoglobin concen-
tration.19 It also allows variation in hydrolysis to be
accounted for. Once the method was optimized, 1714
samples from the BRHS were analysed.
Results and discussion
Isolation and detection
Mean Pearson correlation coefficients, mean response
factors (gradients) and mean y-intercepts for protein-
bound CML and lysine calibration were calculated
(Table 1).
Separation of CML from the closely eluting peak,
suspected to be valylserine or serylvaline, was good in
most (1614 [97%]) samples (Figure 1). Valylserine and
serylvaline are dipeptides composed of valine and
serine with the same molecular formula (C8H16N2O4)
and m/z as CML and are likely to be produced during
acid hydrolysis. Since this is an isobaric interference,
reduction of the mass extraction window cannot elim-
inate this interferent. The CML and CML-d4 appear to
have isomerized, resulting in two peaks with the same
m/z at two different retention times (1.86 and 2.38min).
The peak with the latter retention time was chosen for
integration due to better peak shape.
Limits of blank, detection and quantification
In IDMS, the lower limit of detection (LLOD) and
quantification (LLOQ) are usually determined by cal-
culating the signal to noise ratio (SNR) in a spectrum,
with an SNR of 3 being used as an LLOD and an SNR
of 10 (with accuracy of 80–120% and <20% impreci-
sion) being used as an LLOQ.8 Due to the signal proc-
essing of the Orbitrap Exactive, with baseline removal
inherent in Orbitrap data acquisition, there is generally
no noise in the extracted ion chromatogram.11
Therefore, the SNR for all peaks was infinity, and
SNR cannot be used to estimate LLOD and LLOQ.
Instead, the LLOD and LLOQ were estimated based
on the slope and SD of the y-intercept of the calibra-
tion curve.20
In the lowest water-based calibrator sample
(0.25 lM), the mean CML concentration (over 21
batches) was 0.29 lM (<20% bias), with an inter-
assay coefficient of variation (CV) of 10.1% (<20%
variation). In the water-based calibrators, the results
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Figure 1. Extracted-ion-chromatograms (0–5 min): (a) Close-up of CML (and other metabolites) in serum with m/z of 205.1183 and
retention time of 2.39 min (note splitting of the CML peak [at 1.87 and 2.39 min] and closely eluting peak thought to be valylserine or
serylvaline; (b) CML (and other metabolites) in serum with m/z of 205.1183 and retention time of 2.39 min; (c) deuterated CML in
serum with m/z of 209.1343 and retention time of 2.38 min (note splitting at 1.86 and 2.38 min); (d) lysine in serum with m/z of
147.1128 and retention time of 3.11 min; (e) universally labelled 13C-lysine in serum with m/z of 153.1329 and retention time
of 3.11min.
CML: carboxymethyl lysine.
Table 1. Figures demonstrating assay performance and median concentration observed in BRHS plasma samples.
CML Lys CML (normalized)
Calibration
Pearson correlation coefficient (r2) (SD) 0.9994 (0.003) 0.9993 (0.0008) NA
Gradient (SD) 0.0223 (0.0102) 0.0016 (0.0007) NA
Intercept (SD) 0.0020 (0.0008) 1.146 (1.18986) NA
Water-based QC
Measured concentration (lM) 0.29 2,377 NA
Inter-assay CV (%) 10.1 18.3 NA
Estimated LOB (lM) 0.13 136 NA
Estimated LOD (lM) 0.12 1250 NA
Estimated LOQ (lM) 0.16 3789 NA
Chosen LOQ 0.25 2500 NA
Serum based QC
Intrasample CV 2.7 2.1 3.9
Intra-assay CV 17.2 9.3 10.5
Inter-assay CV 18.1 14.8 16.2
BHRS plasma samples
Median measured Concentration (lM) 2.5 39,773.5 65
Interquartile range (lM) 2.0 to 3.2 36,109 to 43,210.6 54 to 76
Estimated reference range (lM) 1.1 to 5.6 26,182 to 57,677 34 to 123
CML: carboxymethyl lysine; LOQ: limit of quantification; LOB: limit of blank; LOD: limit of detection.
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were linear between 0.25 lM and 10 lM. The limit of
blank (LOB) for the zero-calibrator sample was esti-
mated as 0.13 lM based on an average concentration
of 0.04 lM and a standard deviation of 0.06
(LOB¼meanþ 1.645 SD).21 The LLOD was estimated
as 0.12 lM, by multiplying the SD of the y-intercept by
3.3 and dividing by the slope of the calibration curve.20
The LLOQ was estimated as 0.16 lM, by multiplying
the SD of the y-intercept by 10 and dividing by the
slope of the calibration curve.20 The concentration of
the lowest water-based calibrator (0.25 lM) was chosen
as the LLOQ, in order to avoid extrapolation,22 since
CML is endogenous to serum samples. Only one
plasma sample was observed with a CML concentra-
tion below the LLOQ of 0.25 lM. Thirteen samples
were observed with a CML concentration of over
10 lM (ranging between 11.9 and 17.4 lM). Since
there was no evidence of detector saturation with the
closely eluting isobaric contaminant peak present at
approximately 1000 times higher concentrations
(based on peak area), the linearity can be extrapolated.
In the lowest water-based calibrator sample, the
mean lysine concentration (over 21 batches) was
2377 lM (<5% bias), with an inter-assay CV of
18.3% (<20%).22 In the water-based calibrators, the
results were linear between 2500 lM and 100,000 lM.
The LOB for the zero-calibrator sample was estimated
as 136 lM based on an average concentration of
–539 lM and an SD of 410 (LOB¼meanþ 1.645
SD).21 The LLOD was estimated as 1250lM, by mul-
tiplying the SD of the y-intercept by 3.3 and dividing by
the slope of the calibration curve.20 The LLOQ was
also estimated as 3789 lM, by multiplying the SD of
the y-intercept by 10 and dividing by the slope of the
calibration curve.20 The concentration of the lowest
water-based calibrator, 2500 lM, was chosen as the
LLOQ, in order to avoid extrapolation,22 since lysine
is endogenous to serum samples. No serum samples
were observed with a lysine concentration below
2500 lM (all  8,343 lM). No serum samples were
observed with a lysine concentration over 100,000 lM
(all  58,231 lM).
Serum-based QC
Six serum QC samples were prepared and re-injected 16
times each. The mean intra-assay, intra-sample CVs
were 2.7% for CML, 2.1 for lysine and 3.9% for nor-
malized CML. This demonstrates that repeated analy-
sis of the same sample preparation is robust. The CVs
for normalized CML are increased, since the variability
of both the CML measurement and the lysine measure-
ment is contributing to the overall variability.
The intra-assay CV (based on 30 freshly prepared
and reconstituted samples, each injected only once)
was 17.2% for CML, 9.3% for lysine and 10.5% for
CML normalized to lysine. The CV for normalized
CML is lower than that of directly measured CML in
serum samples, as normalization accounts for variation
incorporated during individual sample preparation.
The overall inter-assay CV was 18.1% for CML,
14.8% for lysine and 16.2% for CML: lysine. The
inter-assay CVs for CML (directly measured and nor-
malized) are outside the target CV of 15% recom-
mended by Food and Drug Administration and other
guidelines for validation of bioanalytical methods
within regulated environments.22 In non-regulatory
environments, a CV of 20–25% is a commonly used
target.23 The variation may have been introduced
during high-throughput sample preparation, particu-
larly during hydrolysis or during HRAM MS analysis.
It is recommended that the normalized CML con-
centration is used for clinical research studies, as it
accounts for variation in sample preparation and in
blood total protein concentrations. This is analogous
to reporting HbA1C in relation to haemoglobin
concentration.19
To assess the variability of the HRAM MS analysis
and the sample preparation, a serum-based QCwas pre-
pared and run with every plate. The normalized CML
concentration obtained was within QC limits, according
to the Westguard Multi-rules, for all but one batch, and
all but three within 2 SD of the mean of 12 run-in sam-
ples (Figure 2). Unfortunately, in some runs, this serum
QC sample was contaminated – either from an
unknown contaminant eluting over a wide retention
range or from co-elution of the isobaric peak (suspected
to be valylserine or serylvaline) (Figure 1).
Batch-to-batch variation
Since no external or commercial QC material exists, the
overall mean, median and interquartile range (IQR)
was monitored for each batch of 95 samples to check
for batch effects. The batch-to-batch values are
expected to vary, since each batch includes different
samples; however, no obvious trends were observed
in normalized lysine concentration (Figure 3).
To attempt to investigate the stability of the dried
hydrolysed samples, 12 samples which were stored for
three months at –80C were reconstituted with NFPA
and analysed by HRAM MS. The mean CML, lysine
and normalized CML concentrations were not signifi-
cantly different. To check for unwanted trends in the
data over time, the box plots were arranged by date run
on the LC-MS, by date of sample preparation and by
delay between sample preparation and LCMS run. No
obvious trends were observed (data not shown).
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Figure 2. Levy-Jennings plot displaying the variability of the measured concentration of CML (normalized to the measured lysine
concentration) in the quality control serum samples run with every batch. The mean normalized CML concentration derived from
previous analysis of 12 quality control serum samples is referenced as the grey line. The green, yellow and red lines reference the
mean 1 2 and 3 SD, respectively. Note for some runs co-elution with an isobaric interferant or contamination of the QC sample
meant that CML concentration could not be measured.
CML: carboxymethyl lysine.
Figure 3. Box plots showing median (line), box (interquartile range) and whiskers (<1.5 IQR) for normalized CML concentration
in BRHS plasma samples run in each batch, arranged by plate number (n¼ 95 per batch). The circles represent outliers (<3 IQR)
and the stars represent extreme outliers (>3 IQR). No obvious trends are observed from batch to batch; samples were ran-
domized before sample preparation. Normalized CML concentrations of  200 mM/M lysine were excluded from the figure for clarity.
CML: carboxymethyl lysine.
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EDTA plasma versus serum samples
Paired samples of serum (serum separator vacutainers)
or plasma (KþEDTA vacutainers) from seven healthy
volunteers were run in triplicate (Table 2). The concen-
trations observed were not statistically significantly dif-
ferent for all three analytes. CML concentrations were
also found to be similar in plasma versus serum sam-
ples in a previous study.4
Throughput
We developed a 96-well deep-well method of sample
preparation based on previously published methods
individual tube methods.1 The hands-on preparation
time (not including incubations) is reduced more than
five-fold compared with the estimated sample prepara-
tion time reported for individual tube methods1
(Table 3). It also uses lower volumes of reagents. MS
analysis time is slightly increased: 9-min run compared
with the 7.5-min run published.4 However, analysis of a
96-well plate can still be completed within an over-
night run.
Comparison with other IDMS methods
The CML concentration was measurable in 1664 sam-
ples from the BRHS. For 50 samples (3%), the CML
peak co-eluted with the isobaric peak (suspected to be
valylserine or serylvaline) or there was broad contam-
ination. The CML and normalized CML concentra-
tions were positively skewed and results for lysine
were negatively skewed (Figure 4).
A mean of 2.7 lM (full range: 0.2–17.4 lM) with an
SD of 1.4 lM and a median of 2.5 lM (IQR: 2.0–
3.2 lM) was found for CML concentration in the
BHRS samples (n¼ 1664). A reference range of 1.1 to
5.6 lMwas calculated (mean 1.96 SD, after log trans-
formation). It should be noted that the samples
obtained at the 30th year re-examination of the
BRHS were from white European males aged 71 to
92 years and that up to 444 of the participants had a
diagnosis of CVD.17
The mean CML concentration of 2.7 lM measured
is similar to the mean of 2.8 lM (SD 0.4lM), previous-
ly reported for 10 healthy controls1 (Table 4). The
BRHS median CML concentration of 2.5 lM is also
similar to the median concentration of 2.9lM (range
1.7 to 4.4lM) observed in 31 individuals with type 1
diabetes mellitus with normal renal function.5
The mean lysine concentration in the BHRS samples
was 39,490.5 lM, with an SD of 6268.6 lM, after
hydrolysis. The median was 39,773.5 lM (IQR:
36,109.0–43,210.6). A reference range of 26,182 to
57,677 lM was calculated (mean 1.96 SD, after log
transformation). To our knowledge, no reference
ranges have been reported for lysine concentration in
serum or plasma hydrolysate, as this is not a physio-
logically relevant measure. The lysine concentration
correlated with the albumin concentration (r2¼ 0.24),
demonstrating that variation in protein concentration
and variation in sample preparation contribute to the
variation in lysine concentration.
A mean normalized CML concentration of 69lM/M
lysine (range: 19–453; SD 34) was reported in the BRHS.
The median was 65lM/M lysine (IQR: 54–76). A refer-
ence range of 34 to 123lM/M was estimated from the
log-transformed data (mean 1.96 SD).
The median normalized CML concentration of
65 lM/M lysine measured is similar to the median of
68 lM/M lysine, previously reported for 18 sedentary
individuals26 (Table 4). It is also broadly similar to the
medians of 51 lM/M lysine and 80 lM/M lysine
reported for 70 individuals in the top and bottom tertile
of AGE score, respectively.29
The mean of 69 lM/M lysine observed in the BRHS
samples was far lower than the medians reported by
Hull et al.: 132 to 140 lM/M lysine4 (Table 4). They
measured lysine concentration using IDMS; however,
they did not report the raw CML or lysine
Table 2. Comparison of results from paired serum and EDTA plasma samples (seven paired samples run in triplicate).
Results of paired t-test demonstrated no significant (ns) difference between the two sample types.
CML (lM) Lys (lM) CML (lM/M lys)
Serum (n¼ 7) (mean [SD]) 2.543 (0.44) 44,881 (3646) 57 (8.0)
EDTA plasma (n¼ 7) (mean [SD]) 2.509 (0.37) 44,675 (2506) 56 (6.5)
P (paired t-test) 0.665 (ns) 0.740 (ns) 0.697 (ns)
EDTA: ethylenediaminetetraacetic acid; CML: carboxymethyl lysine.
Table 3. Comparison of hands-on sample preparation time
using the 96-well versus individual tube method and comparison
of HRAM MS analysis time for 1000 samples.
Per 1000 samples
Traditional
method (hr)
HT
method (h)
Sample preparation (hands-on) 150 26
Chromatography and detection 125 150
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concentrations observed. Their range is based on
repeated analysis of a pooled sample from 10 healthy
volunteers analysed under different preanalytical con-
ditions, none of which were found to significantly affect
the CML concentration.4 It is also far lower than the
mean of 158 lM/M lysine reported in 21 healthy chil-
dren25 and lower than the mean of 83 lM/M lysine
reported in 44 ex-smokers30 and of 93 lM/M lysine
reported in 169 individuals without diabetes.31
The median normalized CML concentration is
about double that reported by Hanssen et al.6:
34 lM/M lysine (IQR: 29 to 39) based on 558 individ-
uals without prior CVD. They derivatized CML with 1-
butanol: HCl, as an alternative to using NFPA as an
ion-pairing agent, before IDMS analysis. The sample
was split after hydrolysis and the lysine concentration
was measured separately, again using IDMS. Hanssen
et al. did not report the raw CML or lysine
Figure 4. Histogram of (a) CML concentration (lM); (b) lysine concentration (lM); (c) normalized CML concentration (lM/M
lysine) in 1664 BRHS EDTA plasma samples.
CML: carboxymethyl lysine.
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concentrations observed. Perhaps incomplete derivati-
zation or differences in sample population account for
the difference in ranges observed between our study
and theirs. It is also approximately double that
reported for over 200 individuals in the top tertile for
diastolic function28 and more than double that
reported in five healthy individuals.34
Conclusion
CML is a challenging AGE to measure, as it is being
detected in the presence of other amino acids (including
lysine) present at 1000 times higher concentrations in
the sample. However, the results suggest that this is a
robust method for the quantification of CML (normal-
ized to lysine), despite reducing the hands-on time (and
reagent volumes used) for sample preparation substan-
tially. There are no gold standard methods available
for comparison at present, only ELISAs and other
IDMS methods. Our method appears to compare rel-
atively well to other IDMS-based methods. At present,
we recommend this method for research use only.
Further work is required in clinical research to deter-
mine whether CML is indeed a useful biomarker. The
increased throughput provided by this sample prepara-
tion method will aid this endeavour. If CML is a useful
biomarker, then it will be appropriate to evaluate
whether the improved mass accuracy of an ultra high-
resolution instrument is better for sensitivity and selec-
tivity than a triple quadrupole instrument for
this analyte.
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